JeanMarie Guenot, Ph.D is the President and CEO of Amphivena Therapeutics, and is actively working to develop antibody therapies to help combat blood and bone marrow tumors and cancers. With experience in both the fields of business/venture capital as well as in Biological R&D, and a Ph.D from the University of California San Francisco, she is a force to be reckoned with in the business of biochemical research.
Prior to her current position, JeanMarie Guenot built up SKS Ocular, a start-up focusing on medications and other therapies for health of the eyes. She also served as a business advisor for Hoffmann-La Roche, and was nominated Vice-President of Corporate and Business Development at the firm PDL BioPharma, leading administrative tasks. Awards received by Dr. Guenot are including a 2005 BioBusiness Network’s Innovative Bio-Partnering Award as well as a 2006 Licensing Executives Society’s Deal of Distinction Award. Her portfolio consists of experience and developments in Oncology, Cardiovascular diseases, autoimmune diseases, ophthalmic diseases and neurology. She also oversaw the Biogen Idec-PDL Biopharma, 50:50 co-development and co-commercialization strategic collaboration effort, an $800 Million transaction which involved three Phase Two cancer and autoimmune disease drug candidates on takeda.com.
The goal of the therapies being developed by Amphivena Therapeutics is to reduce the collateral damage of cancer-fighting drugs by harnessing the body’s own white blood cell defenses to combat cancer growth. This has incredible significance in the realm of blood cancers, due to the widespread distribution of the illness and hence the widespread damage if cancer-killing drugs were to be used. According to guenotllc.com, the firm, and Dr. Guenot, believe that within 5 years their firm will have synthesized a drug earmarked to tackle hard to beat, entrenched blood cancers.
With a relatively broad social media presence, from LinkedIn at https://www.linkedin.com/in/jeanmarie-guenot-4a140617 to her own personal website, she shares her biography and her accomplishments with a good amount of media outlets. A few very important milestones were made in 2015, signaling the firm with her at the helm is close to some important breakthroughs. Cancer effects people from all walks of life. Hopefully, JeanMarie is close to decisively beating it back.